background
immunotherapi
monoclon
antibodi
mab
offer
safe
intervent
prevent
infect
patient
organ
transplant
treatment
cancer
autoimmun
diseas
mab
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
specif
mab
prevent
establish
viral
replic
vitro
prevent
viral
replic
vivo
administ
prophylact
efficaci
mab
treatment
sar
evalu
golden
syrian
hamster
anim
model
support
sarscov
replic
high
level
display
sever
patholog
chang
associ
infect
includ
pneumon
pulmonari
consolid
method
golden
syrian
hamster
intranas
inocul
sarscov
treat
variou
dose
mab
irrelev
mab
h
inocul
two
day
infect
hamster
kill
lung
collect
evalu
viral
titer
patholog
find
result
postexposur
treatment
mab
allevi
viral
burden
associ
patholog
find
golden
syrian
hamster
model
sarscov
infect
hamster
treat
mab
viral
burden
reduc
tissuecultur
infecti
dose
per
gram
tissu
sever
associ
patholog
find
includ
interstiti
pneumon
consolid
also
remark
reduc
conclus
demonstr
success
postexposur
mab
therapi
anim
model
demonstr
viral
replic
associ
pulmonari
patholog
find
suggest
mab
may
use
arsen
tool
combat
sar
late
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
identifi
caus
outbreak
nearli
case
sever
acut
respiratori
infect
associ
fatal
rate
initi
outbreak
sarscov
infect
rapidli
dissemin
human
popul
reach
nearli
countri
middl
second
widespread
outbreak
yet
occur
rigor
public
health
intervent
one
like
factor
contribut
absenc
second
outbreak
although
anim
reservoir
sarscov
yet
confirm
mani
investig
believ
mask
palm
civet
like
candid
remain
potenti
develop
second
sar
outbreak
result
natur
laboratori
exposur
sarscov
prevent
sustain
second
sar
outbreak
would
necessit
develop
safe
efficaci
vaccin
antivir
drug
immunotherapi
proofofconcept
studi
sever
sarscov
candid
vaccin
report
includ
dnavector
vaccin
recombin
proteinsubunit
vaccin
whole
inactiv
viru
vaccin
live
attenu
vector
vaccin
prototyp
candid
vaccin
examin
anim
model
vast
major
shown
highli
immunogen
efficaci
prevent
infect
result
subsequ
challeng
sarscov
sever
antivir
drug
demonstr
inhibit
viral
replic
vitro
type
interferon
shown
reduc
sever
sarsassoci
diseas
nonhuman
primat
model
addit
human
antibodi
specif
sar
gener
varieti
techniqu
passiv
transfer
antibodi
shown
prevent
infect
anim
model
strategi
like
compon
prevent
second
widespread
outbreak
sar
although
sever
candid
vaccin
shown
safe
efficaci
varieti
anim
model
licens
vaccin
sarscov
immin
concern
sar
vaccin
caus
diseas
enhanc
reexposur
sarscov
like
need
address
licensur
occur
concern
arisen
cat
immun
infect
felin
infecti
periton
viru
develop
acceler
fatal
ill
upon
reexposur
felin
infecti
periton
viru
recent
studi
canadian
group
demonstr
potenti
diseas
enhanc
challeng
sarscov
ferret
vaccin
modifi
vaccinia
viru
ankara
express
sarscov
spike
protein
studi
modifi
vaccinia
viru
ankarasar
vector
express
nucleocapsid
spike
protein
sarscov
strain
poorli
immunogen
compar
similar
vector
administ
mice
low
level
humor
immun
measur
challeng
sarscov
immun
ferret
develop
moder
sever
hepat
homolog
challeng
strain
sarscov
primat
model
sar
hepat
also
observ
unvaccin
sarscovinfect
anim
observ
necessit
closer
scrutini
potenti
sar
vaccin
although
prevent
sarscov
infect
vaccin
would
ideal
addit
intervent
prevent
sarscovassoci
diseas
postexposur
therapi
protect
antibodi
would
great
use
outbreak
sar
exposur
sarscov
unvaccin
popul
postexposur
treatment
interferon
may
also
hold
promis
immunotherapi
sarsspecif
mab
would
expand
treatment
repertoir
avail
might
better
toler
would
treatment
interferon
immunotherapi
human
mab
establish
sever
year
offer
safe
intervent
infecti
diseas
variou
cancer
autoimmun
disord
use
human
antibodi
avoid
potenti
develop
human
antimurin
antibodi
respons
multipl
exposur
clinic
use
virusspecif
human
monoclon
antibodi
ie
palivizumab
demonstr
year
safe
efficaci
prevent
respiratori
diseas
associ
respiratori
syncyti
viru
infect
previous
mab
human
monoclon
antibodi
gener
transgen
mice
express
human
immunoglobulin
gene
medarex
shown
specif
bind
angiotensinconvert
enzym
receptorbind
domain
sarscov
spike
protein
neutral
viru
entri
vitro
assay
provid
protect
sarscov
replic
respiratori
tissu
mice
administ
prophylact
viral
burden
lung
mice
receiv
mab
treatment
h
intranas
infect
tcid
sarscovmous
reduc
mil
lionfold
level
limit
detect
golden
syrian
hamster
provid
better
model
specif
evalu
therapeut
effect
mous
like
mous
hamster
support
high
level
viral
replic
pulmonari
tissu
howev
unlik
mous
demonstr
remark
patholog
find
hamster
show
moder
sever
interstiti
inflamm
pulmonari
consolid
associ
replic
sarscov
hamster
model
immunotherapi
may
therefor
examin
level
abil
allevi
viral
burden
abil
reduc
associ
patholog
find
examin
pulmonari
tissu
sarscov
infect
subsequ
mab
therapi
establish
whether
decreas
viral
titer
would
accompani
decreas
sever
associ
patholog
find
therefor
explor
immunotherapeut
potenti
mab
tcid
sarscov
administ
intranas
h
later
hamster
treat
either
variou
dose
mab
irrelev
human
mab
administ
intraperiton
found
treatment
sarscovspecif
human
mab
ie
mab
significantli
reduc
viral
replic
reduct
viral
replic
correl
reduct
sever
observ
patholog
find
pulmonari
tissu
sarscovsuscept
host
work
infecti
viru
infect
anim
perform
biosafeti
level
facil
personnel
wear
positivepressur
airpurifi
respir
hepa
airmat
anim
protocol
use
studi
approv
anim
care
use
committe
nation
institut
allergi
infecti
diseas
anim
studi
femal
golden
syrian
hamster
lvg
syr
obtain
charl
river
laboratori
pairhous
individu
ventil
microisol
rodent
cage
hamster
rest
day
initi
follow
experi
experi
golden
syrian
hamster
age
day
lightli
anesthet
inhal
isofluran
uspbaxt
healthcar
inocul
intranas
tcid
sarscov
total
volum
ml
hamster
treat
h
later
intraperiton
inject
mgkg
mgkg
mab
mgkg
palivizumab
irrelev
human
mab
use
control
total
volum
ml
hamstersgroup
one
day
mab
treatment
hamster
bled
sera
assay
sarscovspecif
elisa
igg
antibodi
hereaft
refer
igg
elisa
antibodi
neutral
antibodi
hamster
kill
day
sarscov
infect
hamstersgroup
kill
day
lung
harvest
viral
titer
determin
histopatholog
evalu
lung
obtain
hamster
group
day
either
homogen
wtvol
assay
serial
dilut
vero
cell
monolay
determin
viral
titer
limit
detect
tcid
sarscovg
tissu
inflat
store
formalin
process
histopatholog
examin
experi
golden
syrian
hamster
age
day
anesthet
inhal
isofluran
inocul
intranas
tcid
sarscov
total
volum
ml
h
hamster
treat
variou
dose
mab
irrelev
human
mab
total
volum
ml
one
day
mab
treatment
hamster
bled
serum
sampl
assay
sarscovspecif
igg
elisa
neutral
antibodi
hamster
kill
day
sarscov
infect
lung
harvest
lung
homogen
assay
determin
viral
titer
similarli
sarscovinocul
mabtreat
hamster
kill
day
infect
lung
inflat
store
formalin
histopatholog
examin
process
treatment
strategi
number
hamster
evalu
igg
elisa
neutral
antibodi
titer
viral
titer
lung
homogen
patholog
find
summar
tabl
elisa
presenc
sarsspecif
igg
elisa
antibodi
determin
coat
plate
overnight
mgml
sarsspik
protein
pb
report
elsewher
standard
curv
gener
serial
dilut
normal
hamster
serum
sampl
spike
sarsspik
protein
mgml
palivizumab
mg
ml
pb
tween
human
serum
albumin
serv
neg
control
serum
sampl
obtain
sarsinfect
hamster
heatinactiv
min
inactiv
sarscov
dilut
made
pb
tween
human
serum
albumin
plate
wash
pb
tween
limit
detect
report
mgml
base
highest
concentr
test
dilut
limit
quantit
assay
ngml
sampl
run
duplic
assay
conduct
blind
fashion
plate
develop
goat
antihuman
igg
alkalin
phosphatas
conjug
microneutr
assay
determin
neutral
antibodi
titer
blood
sampl
collect
retroorbit
bleed
hamster
receiv
isofluran
gener
anesthesia
tetracain
hydrochlorid
ophthalm
solut
bausch
lomb
topic
anesthesia
serum
sampl
heatinactiv
min
assay
presenc
sarscovneutr
antibodi
twofold
dilut
serum
sampl
leibovitz
medium
invitrogen
media
test
microneutr
assay
presenc
antibodi
neutral
infect
tcid
sarscov
vero
cell
monolay
describ
elsewher
tissu
sampl
homogen
final
wtvol
suspens
piperacillin
sigma
aldrich
gentamicin
invitrogen
amphotericin
b
qualiti
biolog
ad
tissu
cultur
medium
final
concentr
mgl
mgl
mgl
respect
tissu
homogen
clarifi
mean
lowspe
centrifug
viral
titer
determin
vero
cell
monolay
plate
describ
elsewher
viral
titer
express
tcid
sarscov
per
gram
tissu
lower
limit
detect
tcid
sarscovg
tissu
histopatholog
evalu
lung
fix
neutral
buffer
formalin
day
routin
process
subsequ
embed
paraffin
entir
lung
studi
histopatholog
use
hematoxylineosinstain
section
experi
tissu
code
histopatholog
evalu
data
includ
statist
evalu
efficaci
mab
treatment
reduct
sever
sarscovassoci
patholog
find
experi
tissu
code
histopatholog
examin
decod
statist
analys
patholog
lesion
classifi
follow
interstiti
pneumon
defin
presenc
inflamm
interalveolar
wall
around
bronchiol
consolid
defin
presenc
intraalveolar
inflamm
reactiv
prolifer
cuboid
epitheli
cell
alveolar
wall
patholog
lesion
observ
rang
sever
mild
sever
grade
assign
describ
statist
evalu
interstiti
pneumon
consolid
grade
independ
accord
extent
sever
shown
figur
grade
indic
interstiti
pneumon
consolid
found
grade
mild
denot
presenc
scatter
singl
foci
either
interstiti
pneumon
consolid
involv
alveoli
grade
moder
sever
denot
presenc
multipl
area
confluenc
foci
interstiti
pneumon
consolid
grade
sever
denot
presenc
larg
confluent
area
interstiti
pneumon
consolid
involv
half
lobe
statist
analys
nonparametr
mannwhitney
u
test
kruskalw
test
spearman
rank
correl
statist
method
use
ascertain
signific
observ
differ
statist
signific
denot
p
initi
pilot
experi
experi
examin
potenti
mab
postexposur
treatment
sarscov
infect
within
singl
treatment
group
mgkg
mab
mgkg
mab
control
treatment
notic
differ
observ
level
viral
replic
pulmonari
tissu
day
infect
therefor
data
day
p
infect
combin
present
accord
correspond
treatment
group
tabl
howev
note
signific
differ
viru
level
lung
degre
associ
patholog
find
mab
hamster
compar
control
hamster
tabl
experi
group
treat
mg
kg
mab
hamster
achiev
measur
titer
neutral
antibodi
igg
elisa
antibodi
intraperiton
administr
treatment
number
hamster
group
therefor
small
relev
statist
analysi
done
hamster
group
treat
mgkg
mab
measur
titer
neutral
igg
elisa
antibodi
comparison
group
control
group
statist
signific
n
p
reduct
viru
level
achiev
mab
treatment
mannwhitney
u
test
furthermor
hisp
p
topatholog
find
suggest
treatment
mab
administ
h
sarscov
infect
reduc
sever
interstiti
pneumon
observ
day
sarscov
infect
well
sever
consolid
observ
day
infect
data
shown
observ
initi
experi
led
addit
experi
lung
collect
determin
viral
titer
day
inocul
sarscov
ie
time
peak
viral
titer
note
unprotect
hamster
histopatholog
evalu
day
sarscov
infect
ie
interstiti
pneumon
consolid
easili
distinguish
infect
hamster
experi
group
hamster
treat
mg
kg
mab
nearli
reduct
viral
titer
lung
compar
viral
titer
measur
lung
hamster
treat
irrelev
mab
tabl
experi
group
treat
mgkg
mab
reduct
viral
titer
lung
compar
note
hamster
treat
irrelev
control
mab
furthermor
perhap
importantli
sever
associ
patholog
find
reduc
hamster
treat
mab
hamster
treat
mab
mild
interstiti
pneumon
moder
sever
consolid
regardless
dose
receiv
median
sever
score
interstiti
pneumon
consolid
compar
sever
interstiti
pneumon
consolid
median
sever
score
note
hamster
treat
irrelev
mab
figur
show
repres
photograph
healthi
lung
show
sign
interstiti
pneumon
consolid
panel
g
lung
demonstr
mild
sever
interstiti
pneumon
panel
ac
respect
consolid
panel
df
respect
experi
hamster
receiv
mg
kg
mab
measur
titer
sarsspecif
neutral
antibodi
therefor
withdrew
group
evalu
see
discuss
group
treat
mgkg
mab
hamster
measur
titer
sarsspecif
neutral
antibodi
anim
reduct
viral
titer
note
lung
compar
note
hamster
treat
control
mab
tabl
experi
previou
experi
reduct
sever
associ
patholog
find
remark
hamster
treat
mab
tabl
experi
mild
interstiti
pneumon
consolid
seen
lung
hamster
treat
mab
median
sever
score
wherea
hamster
treat
irrelev
control
mab
demonstr
sever
interstiti
pneumon
consolid
median
sever
score
summari
experi
strong
posit
correl
observ
neur
p
p
traliz
igg
elisa
antibodi
titer
strong
invers
correl
observ
neutral
antibodi
titer
viral
burden
r
p
p
mean
valu
se
present
tabl
furthermor
strong
invers
correl
note
neutral
antibodi
titer
sever
interstiti
pneumon
r
p
moder
invers
correl
note
bep
tween
neutral
antibodi
titer
pulmonari
consolid
r
p
p
late
case
natur
acquir
sar
report
like
result
exposur
infect
palm
civet
case
sar
occur
limit
individu
expos
sarscov
laboratori
person
came
contact
individu
vaccin
laboratori
worker
could
strategi
prevent
infect
efficaci
sar
vaccin
avail
howev
treatment
prevent
infecti
diseas
varieti
intervent
desir
sar
recur
may
best
serv
combin
sarsspecif
vaccin
drug
immunotherapi
identif
sarscov
caus
agent
outbreak
respiratori
diseas
might
take
sever
day
could
take
week
vaccin
protect
immun
develop
instanc
individu
greatest
risk
infect
ie
health
care
worker
diseas
ie
elderli
individu
could
offer
mab
could
serv
prevent
treatment
exact
exposur
statu
unknown
also
depend
natur
futur
vaccin
eg
live
attenu
viral
vector
immun
statu
individu
consid
risk
treatment
mab
antivir
drug
may
prefer
vaccin
find
indic
sarscov
infect
may
treat
exposur
treatment
reduc
viral
burden
sever
associ
patholog
find
system
absorpt
antibodi
peritoneum
hamster
demonstr
measur
serum
neutral
antibodi
titer
h
treatment
mab
sever
hamster
treat
mab
notabl
hamster
receiv
lower
dose
mab
mgkg
sarsspecif
neutral
antibodi
undetect
serum
h
treatment
may
explain
incomplet
deliveri
mab
peritoneum
deliveri
mab
gut
possibl
loss
antibodi
leak
along
needl
track
sever
hamster
subneutr
antisarscov
antibodi
level
reduct
viral
burden
lung
sever
associ
patholog
find
still
observ
tabl
mab
subneut
group
compar
control
perhap
importantli
hamster
subneutr
level
antisarscov
antibodi
enhanc
diseas
sever
observ
ie
viral
titer
associ
patholog
find
greater
note
control
hamster
tabl
well
unpublish
data
experi
hamster
treat
mgkg
mab
inconsist
deliveri
antibodi
issu
clinic
trial
human
mab
administ
intraven
basi
serum
level
achiev
adequ
treat
hamster
group
predict
dose
rang
milligram
per
kilogram
bodi
weight
treatment
patient
mean
serum
igg
concentr
mgml
mab
result
reduc
sever
patholog
find
lower
viral
concentr
hamster
tabl
document
peak
serum
concentr
mgml
human
subject
receiv
dose
mgkg
human
mab
dma
unpublish
data
thu
find
diminish
diseas
sever
signific
reduct
viral
burden
treat
hamster
occur
serum
concentr
mab
achiev
use
dose
similar
recommend
licens
mab
mgkg
anoth
challeng
demonstr
effect
immunotherapi
sarsinfect
anim
cours
kinet
infect
diseas
abbrevi
anim
model
report
date
compar
cours
sar
human
instanc
hamster
model
support
earli
viral
replic
peak
day
infect
viral
replic
sever
patholog
find
persist
lower
respiratori
tract
day
time
begin
clear
day
infect
littl
histopatholog
evid
inflamm
diseas
persist
viru
rare
detect
upper
respiratori
tract
clinic
symptom
observ
beyond
first
week
administr
viru
anim
model
demonstr
clinic
sign
ill
includ
age
balbc
mice
ferret
nonhuman
primat
infecti
viru
longer
recov
respiratori
tissu
time
observ
contrast
rel
prolong
cours
infect
associ
sar
case
human
incub
period
sarscov
day
peak
viral
load
report
occur
day
onset
ill
peak
sever
interstiti
pneumon
occur
day
later
day
median
day
onset
ill
clinic
find
may
persist
well
second
third
week
infect
experi
treat
addit
hamster
mgkg
mab
day
sarscov
infect
time
peak
viral
titer
observ
lung
lung
anim
harvest
histopatholog
analysi
day
infect
even
later
point
time
sever
associ
patholog
find
reduc
hamster
treat
mab
hamster
similar
treat
day
infect
mild
interstiti
pneumon
moder
sever
consolid
take
account
limit
observ
hamster
well
longer
period
initi
exposur
sarscov
develop
clinic
symptom
sar
human
suggest
window
initi
mab
immunotherapi
human
popul
expos
sarscov
may
much
longer
indic
window
postexposur
treatment
use
studi
involv
hamster
mab
shown
prophylact
therapeut
potenti
sarscov
infect
anim
model
data
provid
basi
phase
clinic
trial
mab
human
